Up to now, there are more than 400 antibody-drug conjugates (ADC) in the development stage. Among them, the most popular targets is HER2, followed by CLDN18.2, EGFR and TROP2. Here, let's briefly analyze EGFR-directed ADCs.
Like this book? You can publish your book online for free in a few
minutes!